Exciting news! MEC portfolio company Aspen Neuroscience has been featured in the Wall Street Journal for its groundbreaking work in developing stem-cell therapies for Parkinson’s disease. We’re thrilled to see Aspen’s important contributions to the field recognized, and it’s especially significant given that Jeanne Loring, the scientific founder of Aspen, has been a pioneer in stem-cell research for decades.

https://www.wsj.com/articles/stem-cells-parkinsons-disease-heart-failure-60e9e21f

The Aspen management team, led by Damien McDevitt, has done an incredible job translating Jeanne’s groundbreaking research into a company that has the potential to change the lives of millions of people. We are especially proud of our MEC colleague, Kim Kamdar, and her role as the founding CEO of Aspen.  Kim’s strategic vision, leadership, and tireless efforts were instrumental in laying the foundation for Aspen’s success.

We’re passionate about supporting leading scientists and helping them translate their breakthroughs into impactful companies that can improve people’s lives. Creating a supportive ecosystem for entrepreneurship is essential to unlocking the full potential of scientific innovation, and we’re committed to doing our part to make that happen.

At MEC, we believe that great companies are built on the foundation of great science and great leadership. Aspen Neuroscience is a perfect example of this, and we’re honored to be part of their journey. Congratulations to Jeanne, Kim, and the entire Aspen team on this well-deserved recognition!

Check out our prior blog post about our investment in Aspen Neuroscience:

https://medexcelcap.com/cell-therapy-in-cns-why-now/